Československý transplantační kongres
 |
|
1. československý transplantační kongres 2. československý transplantační kongres |
Konferenční abstrakta 2006
Abstrakta posterů – sekce lékařů
THE ROLE OF NON-SPECIFIC IMMUNITY CELLS AND INOS IN MURINE CORNEAL GRAFTS IN EARLY PHASES AFTER TRANSPLANTATION VERSUS REJECTION TIME: COMPARISON OF TACROLIMUS, MYCOPHENOLATE MOFETIL AND AMINOGUANIDINE EFFECTS.
Bysterská P., Svozílková P.1, Farghali H.
Institute of Pharmacology, 1Department of Ophthalmology, 1st Faculty of Medicine, Charles University, Prague
Tx in mice (C57BL/10 to BALB/c) was performed. Therapy included FK506 (0.2mg/kg), MM (30mg/kg) or AMG (0.1g/kg), started at the day of Tx and was injected i.p. daily. Corneas were excised on the 3rd and 7th day after Tx and at the time of rejection. Immunohistological evaluation using antibodies against MPHs, NPHs, DC and iNOS positive cells was performed and corneal grafts were assessed in the peripheries and in the centers separately.
On the 3rd day after Tx, a massive infiltration of MPHs and NPHs into corneal grafts was revealed; the DC infiltration was lower in all treated groups.
Treatment with FK506 and MM led to a significant influence of NPHs in the centers of the grafts, but not of MPHs. In contrast, AMG reduced significantly MPHs migration into allografts on the 3rd day after Tx, whereas NPHs infiltration has not been attenuated. However, immunosuppressants had no influence on infiltration of DC during early phases after Tx.
At the time of rejection MPHs and NPHs infiltration is lower in every group, whereas the number of DC remains constant.
iNOS positivity was not measured in corneas which were excised during early phases after Tx according to our previous negative studies. In rejected corneas iNOS positive cells were detected both in treated groups and in control groups. The only treatment which reduces efficiently the infiltration of iNOS positive cells both to the periphery (p<0.05) and to the centre (p<0.05) of the rejected graft comparing with control saline group was FK506 therapy.
This study was supported by Grants GAČR 305/03/D130 and VZ MSM 0021620807.